갈라파고스 (GLPG) 주가

갈라파고스(GLPG)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $28.91 (+5.01%), 시가총액 $1.86B, PER (주가수익비율) 3.19, 52주 최저~최고 $25.07 ~ $37.62.

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Be

핵심 지표

• 현재가: $28.91 (+5.01%)
• 시가총액: $1.86B
• PER (주가수익비율): 3.19
• 52주 최저~최고: $25.07 ~ $37.62
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

갈라파고스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

갈라파고스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 2.5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.50
• 순이익률: 0.47%
• 영업이익률: -9.83%

자주 묻는 질문